紫外分光光度法测定洛索洛芬钠片中洛索洛芬钠的含量

目的：建立紫外分光光度法测定洛索洛芬钠片中洛索洛芬钠含量的方法。方法：采用紫外分光光度法,以水为空白对照,检测波长为223 nm,测定洛索洛芬钠的吸光度。结果：洛索洛芬钠浓度在6.384～21.280μg/ml范围内线性关系良好（r=0.999 9,n=6）,平均回收率99.58%,RSD为0.81%。结论：该法操作快速简便,结果准确,适于洛索洛芬钠片中洛索洛芬钠含量的快速测定及质量控制。     

紫外分光光度法测定洛索洛芬钠片的含量

目的：建立洛索洛芬钠含量的紫外分光光度测定法。方法：采用紫外分光光度法,以水为空白对照,223nm为测定波长,测定洛索洛芬钠的含量。结果：洛索洛芬钠浓度在4.016～20.080μg/ml范围内线性关系良好（r=0.9994,n=5）,平均加样回收率99.13%。结论：该法操作简便、精密度好、结果可靠,适用洛索洛芬钠片含量的快速测定。     

紫外分光光度法测定洛索洛芬钠片的含量

目的:建立用紫外分光光度法测定洛索洛芬钠片含量的方法。方法:以水为溶剂,测定波长为223nm。结果:检测线性范围为4.01616.064μg/mL,r=0.9997。平均回收率为98.81％,RSD=1.19％。结论:本方法准确、快速、简便,可用于洛索洛芬钠片的质量控制。     

紫外分光光度法测定洛索洛芬钠的含量

目的建立用紫外分光光度法测定洛索洛芬钠含量的方法。方法以水为溶剂,测定波长为223nm。结果检测线性范围为4.20～25.20μg.mL-1,r=0.9999。平均回收率为99.88%,RSD=0.30%。结论本方法快速、简便、准确,可用于洛索洛芬钠的含量测定。     

多潘立酮片检验方法的探讨

目的测定多潘立酮片含量。方法紫外分光光度法与高效液相色谱法。结果供试品紫外吸收图谱应与对照品紫外吸收图谱一致;高效液相色谱法定性、定量快速准确。结论紫外图谱定性准确,高效液相色谱法专属性强。     

紫外分光光度法和高效液相色谱法测定利巴韦林片含量的比较

目的:建立紫外分光光度法测定利巴韦林片的含量.方法:采用紫外分光光度法和高效液相色谱法分别测定利巴韦林片的含量.结果:紫外分光光度法平均回收率为100.9%,RSD=0.57%(n=5);高效液相色谱法平均回收率为99.9%,RSD=0.86%(n=5).结论:紫外分光光度法简便、快速,两种方法测定结果一致(P＞0.05).     

替硝唑氯化钠注射液含量测定的两种方法讨论

目的:用高效液相色谱法与紫外分光光度法测定替硝唑注射液的含量,对两种方法进行比较。方法:采用高效液相色谱(HPLC法),C18柱,以0.05mol/L磷酸二氢钾溶液:甲醇=80:20为流动相,检测波长为310nm;紫外分光光度(UV法),吸收波长为310nm。结论:紫外分光光度法可有效控制替硝唑的含量。     

安乃近片含量测定方法的探讨

目的评估安乃近片含量测定的几种方法。方法采用氧化还原滴定法,紫外分光光度法,高效液相色谱法对安乃近片含量测定的方法进行比较和研究。结果测定方法不同,含量差异较大。结论紫外分光光度法和高效液相色谱法检测效果好,结果准确。     

紫外分光光度法和高效液相色谱法测定芦氟沙星片含量的比较

目的：建立测定芦氟沙星片含量的方法。方法：采用紫外分光光度法和高效液相色谱法测定芦氟沙星片的含量。结果：紫外分光光度法回收率为99.6％，RSD=0.5%;高效液相色谱法回收率100.1％，RSD=1.7%.结论：两种方法简便、快速，测定结果一致。     

HPLC法测定洛索洛芬钠缓释微丸中洛索洛芬钠的含量

哈药集团三精制药股份有限公司摘要目的:本文通过对洛索洛芬钠微丸的含量测定研究,建立一种高效的含量测定方法,为制备洛索洛芬钠微丸型制剂的安全有效和稳定行提供科学依据。进而为剂型选择,处方设计,工艺及质量控制提供理论基础。方法:采用高效液相色谱法对洛索洛芬钠的含量进行测定。结果:通过方法学考察发现,洛索洛芬钠缓释微丸中洛索洛芬钠的含量稳定性良好,方法适宜。     

洛索洛芬钠片溶出度测定及体内外相关性评价

参照中国药典2005年版溶出度试验第二法，建立了UV法测定洛索洛芬钠片体外溶出度的试验方法，并用HPLC法测定洛索洛芬钠片的人体药物动力学，进行了体内外相关性的评价。结果表明洛索洛芬钠片体内外相关性良好，提示体外溶出度试验方法合理。     

Simultaneous determination of tenoxicam and 2-aminopyridine using derivative spectrophotometry and high-performance liquid chromatography

Derivative spectrophotometry and high-performance liquid chromatography (HPLC) were used to determine tenoxicam and one of its decomposition products (2-aminopyridine) simultaneously and in the presence of each other. The derivative procedure was based on the linear relationship between the tenoxicam concentration and the second derivative amplitudes at 390-348 nm (peak-to-trough) measurement. The 2-aminopyridine was determined through measuring the second derivative amplitude at 241 nm (zero-crossing for tenoxicam). For the HPLC procedure, a reversed-phase C₈ column with a mobile phase composed of 0.02 M sodium acetate-methanol-acetonitrile (11:8:1) with 0.005 M heptane sulfonic acid sodium salt, as an ion pair, was used to separate both compounds with 2,4-dinitrochlorobenzene, as an internal standard, in reasonable time. The flow rate was 1.5 ml min⁻¹ with a programmable ultraviolet (UV) detection at 300 and 375 nm. Both UV derivative spectrophotometric and HPLC approaches were followed for confirming the purity of tenoxicam in bulk and tablets dosage form.     

HPLC法测定洛索洛芬钠渗透泵型控释片的含量

目的建立洛索洛芬钠渗透泵型控释片中洛索洛芬钠的含量测定方法。方法采用HPLC法,色谱柱：日本岛津VP—DOS柱（150mm×4．6mm,5μm）;流动相：甲醇-水-冰醋酸-三乙胺（600：400：1：1）;检测波长：222nm;流速：1．00ml·min^-1;柱温：25℃。结果洛索洛芬钠在30．18～110．66mg·L^-1范围内呈良好的线性关系（r=0．9998）,平均回收率为99．83％,RSD=0．48％（n=9）。结论该方法简便、准确、重现性好。适用于洛索洛芬钠渗透泵型控释片中主药的含量测定。     

A validated LC method for the determination of clopidogrel in pharmaceutical preparations

A stability indicating, reversed-phase high-performance liquid chromatographic method was developed and validated for the determination of clopidogrel in pharmaceutical dosage forms. The determination was performed on a semi-micro column, BDS C8 (250 x 2.1 mm i.d., 5 microm particle size); the mobile phase consisted of a mixture of 0.010 M sodium dihydrogen phosphate (pH 3.0) and acetonitrile (35:65, v/v), pumped at a flow rate 0.30 ml min(-1). The UV detector was operated at 235 nm. The retention times for clopidogrel and naproxen, which was used as internal standard, were 3.08 and 6.28 min, respectively. Calibration graphs are linear (r better than 0.9991, n=6), in concentration range 1.00-3.00 microg ml(-1) for clopidogrel. The intra- and inter-day RSD values were less than 1.96%, while the relative percentage error E(r) was less than 2.0% (n=5). Detection and quantitation limits were 0.12 and 0.39 micro ml(-1), respectively. The method was applied in the quality control of commercial tablets and content uniformity test and proved to be suitable for rapid and reliable quality control.     

维C银翘片中对乙酰氨基酚含量测定方法改进

目的:采用高效液相色谱法(HPLC)测定维C银翘片中对乙酰氨基酚的含量,以避免用双波长分光光度法测定时出现的干扰因素.方法:采用HPLC法,双波长分光光度法分别测定不同批号的维C银翘片中对乙酰氨基酚的含量.结果:双波长分光光度法较繁琐、误差大,HPLC法简便、快速、准确.结论:HPLC法准确可靠,适用于维C银翘片的质量控制.     

Rapid extraction of clenbuterol from human and calf urine using empore C8 extraction disks

In the present paper, disk extraction was evaluated for the rapid isolation of clenbuterol from human and calf urine, followed by high-performance liquid chromatography analysis with UV detection. A method was developed for the extraction with standard density C8 disks. The disks could be washed with 25% methanol in 0.01M sodium hydroxide without significant losses of clenbuterol. The recovery of denbuterol was about 85%, and the extracts were clean. The detection limit was about 10 ng/mL. The main advantages of these disks were the saving of time and the reduced amounts of organic solvents needed.     

First-derivative spectrophotometric and LC determination of cefuroxime and cefadroxil in urine

Two methods are presented for the determination of cefuroxime and cefadroxil in human urine using first (1D) derivative spectrophotometry and high-performance liquid chromatography. Cefuroxime and cefadroxil were determined by measurement of their first-derivative amplitude in 0.1 N sodium hydroxide at 292.5 and 267.3 nm, respectively in the concentration range of 2-10 microg ml(-1) for each drug. The HPLC method depends upon using a LiChrospher 100 RP-18 (5 microm) column at ambient temperature for cefuroxime and 35 degrees C for cefadroxil with mobile phases consisting of water-acetonitrile-acetic acid (85:15:0.1 v/v) at a flow rate of 1.5 ml min(-1) for cefuroxime; and 0.02 M potassium dihydrogen phosphate-acetonitrile (95:5 v/v) containing 0.003% (w/v) hexanesulphonic acid sodium salt and adjusted to apparent pH 3 with phosphoric acid at a flow rate of 2 ml min(-1) for cefadroxil. Quantitation was achieved with UV detection at 275 and 260 nm for cefuroxime and cefadroxil, respectively, based on peak area with linear calibration curves at the concentration ranges of 2-10 microg ml(-1) for cefuroxime and 5-20 microg ml(-1) for cefadroxil. The proposed methods were applied to the determination of dissolution rate for tablets and capsules containing each drug. The urinary excretion patterns as the cumulative amounts excreted have been calculated for each drug using the proposed methods.